-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $80

Benzinga·02/19/2025 14:41:15
Listen to the news
Goldman Sachs analyst Matthew Sykes maintains GeneDx Hldgs (NASDAQ:WGS) with a Neutral and raises the price target from $70 to $80.